央视网消息：在国务院新闻办公室1月23日召开的新闻发布会上，国家知识产权局相关负责人介绍，2025年，我国创新质量持续提升，知识产 权效益加速显现。 截至2025年底，我国国内（不含港澳台）有效发明专利中，高价值发明专利数量达到229.2万件。信息技术管理方法、计算机技术、医学技术 等领域的有效发明专利增速最快，人工智能专利有效量位居全球前列。在量子科技、生物制造、脑机接口、第六代通讯等未来产业，布局了一 批关键核心技术专利。 国家知识产权局副局长芮文彪介绍，全年专利转让许可备案次数达69.7万次，同比增长13.7%。企业发明专利产业化率达到54%，连续多年稳 步增长。2025年1—11月，全国知识产权使用费进出口总额达到3828.7亿元，同比增长7.4%。其中，出口额同比增长23.1%，助力我国服务贸易 出口攀高向新。 最新数据显示，我国专利密集型产业的增加值突破18万亿元，占GDP的比重从2020年的11.97%提升到2024年的13.38%，知识产权的效益加速 显现。 国务院新闻办公室1月23日上午举行新闻发布会，国家知识产权局相关负责人介绍，2025年，我国共授权发明专利97.2万件，发明专利审查周 ...

Investment Rating - The report gives a "Market Weight" rating for the pharmaceutical and biotechnology industry, indicating that the industry index is expected to perform within ±10% of the market index over the next six months [26]. Core Insights - The SW pharmaceutical and biotechnology industry underperformed the CSI 300 index, declining by 0.75% from January 9 to January 22, 2026, which is approximately 0.46 percentage points lower than the CSI 300 index [11]. - Most sub-sectors within the industry recorded positive returns during the same period, with offline pharmacies and raw materials sectors leading with increases of 3.14% and 2.34%, respectively [12]. - Approximately 66% of stocks in the industry recorded positive returns, with the top performer, Baolait, seeing a weekly increase of 60.88% [13]. - The overall price-to-earnings (P/E) ratio for the SW pharmaceutical and biotechnology industry was approximately 52.01 times as of January 22, 2026, showing little change [19]. Summary by Sections 1. Market Review - The SW pharmaceutical and biotechnology industry lagged behind the CSI 300 index, with a decline of 0.75% from January 9 to January 22, 2026 [11]. - Most sub-sectors achieved positive returns, particularly offline pharmacies and raw materials, which rose by 3.14% and 2.34% respectively [12]. - About 66% of stocks in the industry had positive returns, with Baolait leading at a 60.88% increase [13]. - The industry’s P/E ratio was approximately 52.01 times, relative to the CSI 300's P/E ratio of 3.86 times [19]. 2. Industry News - Recent policy changes in Hebei Province have lifted restrictions on the quantity of drugs that hospitals can stock, allowing for more flexibility in drug procurement [24]. - The National Health Commission issued new medical treatment guidelines for trauma and burn victims to enhance emergency response capabilities [22][23]. 3. Company Announcements - Enhua Pharmaceutical announced the approval of a new drug registration certificate for a non-steroidal anti-inflammatory drug, which is expected to reduce the need for opioid pain relief post-surgery [25]. 4. Industry Outlook - The report suggests a focus on investment opportunities in the brain-computer interface sector, which is highlighted in the 14th Five-Year Plan, with ongoing policy support [26]. - Recommended stocks for attention include leading companies in medical devices, pharmaceutical retail, aesthetic medicine, and innovative drugs, among others [28].

Group 1 - The core viewpoint of the article highlights the significant progress made in China's intellectual property (IP) sector by 2025, exceeding the goals set in the 14th Five-Year Plan [3] - By 2025, China is expected to authorize 972,000 invention patents and 1,461,000 utility model patents, with a total of 532 million valid invention patents by the end of 2025, achieving a high-value invention patent ownership of 16 per 10,000 people [3] - The average examination period for trademark registration remains stable at 4 months, with a passing rate exceeding 97%, and the total number of registered trademarks is projected to reach 4,206,000 by 2025 [6] Group 2 - The direct annual output value of geographical indication products in China is close to 1 trillion yuan, marking five consecutive years of growth and contributing significantly to regional economic development [6] - By the end of 2025, China will have recognized 5,066 geographical indication products and approved 7,425 registrations for collective and certification trademarks [8] - The industrialization rate of enterprise invention patents is expected to reach 54% by 2025, with a 13.7% year-on-year increase in patent transfer and licensing registrations [9] Group 3 - China ranks second globally in brand value, with its top 5,000 brands valued at $1.81 trillion [6] - The country has established the largest and most comprehensive network of Technology and Innovation Support Centers (TISC) in collaboration with the World Intellectual Property Organization, with 202 centers [13] - A total of 519 national-level IP public service institutions have been established, covering all provincial levels, and have served over 5 million innovation entities during the 14th Five-Year Plan period [12][13]

Core Insights - The exoskeleton robot industry is experiencing a resurgence, driven by advancements in robotics and AI technology, with a focus on consumer-grade applications and outdoor activities [4][5][7] - Companies like Hypershell, ULS, DNSYS, and ChengTian are emerging as key players in the Chinese exoskeleton market, showcasing their products at major events like CES 2026 [3][4] - Hypershell has positioned itself as a leader in the consumer exoskeleton segment, achieving significant milestones in funding and product delivery [11][13] Industry Overview - Exoskeletons are wearable devices designed to enhance human movement capabilities, with applications primarily in medical rehabilitation and industrial settings [4][5] - The market for consumer-grade exoskeletons is still niche but is gaining traction, particularly among individuals seeking rehabilitation and enhanced mobility [8][11] Technological Developments - Hypershell has introduced innovative products, such as the Hypershell X Ultra, which features advanced AI algorithms and improved battery life, achieving a weight of 1.8 kg and a range of 30 km per battery [13][16] - The industry faces several technical challenges, including the need for better user experience, improved battery life, and the transition from passive to active assistance in exoskeleton functionality [24][26] Market Dynamics - The consumer exoskeleton market is characterized by a lack of standardized regulations, which poses challenges for widespread adoption and market growth [7][8] - Companies are exploring diverse applications for exoskeletons, including outdoor sports, urban commuting, and emergency services, to broaden their market appeal [16][19] Competitive Landscape - Key players in the market include Hypershell, ULS, DNSYS, and ChengTian, each focusing on different aspects of exoskeleton technology, from rehabilitation to outdoor sports [17][21] - The competition is intensifying as new startups enter the market, aiming to innovate and capture consumer interest [5][19]

Core Insights - The article highlights the significant growth and market interest in the Huabao AI ETF (159363), which has reached a scale of 6.303 billion yuan, making it the largest and most liquid AI-themed ETF in the dual innovation sector as of January 22, 2026 [1][4][5]. Fund Performance - The Huabao AI ETF experienced a rapid increase in scale, growing from over 5 billion yuan to over 6 billion yuan within just three trading days (January 14-19, 2026) [1]. - As of January 22, 2026, the ETF's average daily trading volume over the past six months exceeded 800 million yuan, indicating strong market activity [1][4]. Market Position - The Huabao AI ETF has surpassed 24 other similar AI-themed ETFs targeting the ChiNext and Sci-Tech Innovation Board, establishing itself as the "new king" in the dual innovation sector [1][4]. - It is the first ETF in the market to track the "ChiNext AI Index," which reflects the price changes of listed companies related to the AI theme on the ChiNext board [6][7]. Investment Strategy - The ETF is strategically positioned to capture the growth of AI commercialization, with approximately 60% of its portfolio allocated to computing power (primarily optical modules) and 40% to AI applications, effectively covering the entire AI industry chain [7][8]. - The fund manager emphasizes the ETF's dual focus on computing power and AI applications, aiming to benefit from the ongoing growth in AI commercialization [7]. Broader ETF Matrix - Huabao Fund has developed a comprehensive "AI+" ETF investment matrix, which includes various products that cover the entire AI industry chain, such as the Sci-Tech AI ETF and other thematic ETFs focused on financial technology and big data [8][9]. - The matrix also includes ETFs targeting specific applications of AI, such as healthcare and smart driving, indicating a strategic diversification in investment offerings [10][11].

Market Overview - The market has entered a phase of narrow fluctuations after a series of gains, with the Shanghai Composite Index experiencing mild adjustments since January 13. The overall trend remains stable, with orderly rotation among leading sectors [1] - On Thursday, sectors such as commercial aerospace and mining led the gains, while the semiconductor sector showed signs of slowing down. Over 3,500 stocks rose, indicating improved profitability, although trading volume decreased to 2.7 trillion [1] - The current market adjustment is seen as a healthy consolidation for the spring rally, with the focus on maintaining trading volume and the rotation of hot sectors as key factors for sustaining the market momentum [1] Future Outlook - The market is expected to shift from theme-driven to fundamentals-driven momentum, although technology growth will remain the main focus. The leading sectors since the spring rally have been driven by event-based themes like commercial aerospace and brain-computer interfaces, which, despite their long-term potential, lack short-term performance support [1] - As the market enters a consolidation phase, trading volume may decline, prompting a renewed focus on sectors driven by performance and fundamentals. The primary driver for the spring rally remains the increase in market risk appetite, with technology growth sectors expected to lead the way [1] Sector Highlights - In January, technology and raw materials sectors showed strong performance, with high-dividend stocks also being a focus for potential gains in the upcoming quarterly report season [2] - Key areas of interest include AI hardware, which is expected to see significant growth leading up to 2026, and the ongoing trend of robot commercialization, which will expand into various types of robots and related components [2] - The semiconductor industry is on a path toward domestic production, with attention on semiconductor equipment, wafer manufacturing, materials, and IC design [2] - The demand for new energy materials is rising due to rapid growth in domestic and overseas energy storage needs, with signs of supply shortages and price increases expected to continue through 2026 [2] - The innovative drug sector is anticipated to enter a recovery phase after nearly four years of adjustment, with positive net profit growth expected to continue into 2026 [2]

国务院新闻办公室今天上午举行新闻发布会，国家知识产权局披露的知识产权数据，反映出以下主要特 点： 三是知识产权效益加速显现。最新数据显示，我国专利密集型产业的增加值突破18万亿元，占GDP的比 重从2020年的11.97%提升到2024年的13.38%，对经济增长的贡献度稳步提高。全球前5000个品牌中， 我国品牌价值达1.81万亿美元，位居全球第二。地理标志产品直接年产值接近1万亿元，实现五连增， 成为特色产业增收致富的"金名片"，有效助力了区域经济发展。 （总台央视记者 王婧 李晶晶） 一是创新质量持续提升。我国国内（不含港澳台）有效发明专利中，高价值发明专利同比增速比总体水 平高2.2个百分点，数量达到229.2万件。信息技术管理方法、计算机技术、医学技术等领域的有效发明 专利增速最快，人工智能专利有效量居全球前列，在量子科技、生物制造、脑机接口、第六代通讯等未 来产业布局了一批关键核心技术专利，有力促进了高水平科技自立自强。 二是重点区域创新活跃。截至2025年底，长三角地区、京津冀地区和广东省的发明专利有效量分别为 173.4万件、91.6万件和89.9万件，合计约占国内总量的2/3；有效注册商标量 ...

"投资不是简单的资金注入，创投机构需要为创新创业企业提供全方位支持，长期陪伴企业成长。"近 日，东方富海董事长陈玮在接受上海证券报记者采访时表示，创投行业受到的重视程度日益提升，顶层 设计在持续发力，创投行业正被推向"C位"。 当前，科技人才是推动新兴产业、未来产业发展的重要力 量，但其中大部分属于技术型专家，在企业运营管理、市场开拓、财务管理、供应链整合等方面存在短 板。陈玮表示，创投机构应当好"陪驾员"，提供综合服务，帮助他们补好短板。展望"十五五"，东方富 海将坚定投早、投小、投硬科技战略，持续进化投资管理能力，当好中国创新生态的坚定共建者。 顶 层设计将创投推向"C位" "十五五"规划建议提出，"创新监管方式，发展创业投资"。创业投资"风险共 担，利益共享"的特征，与科技创新的风险特性高度适配。新一轮科技革命和产业变革在深入推进，对 创投行业支持科技创新提出了更高也更为迫切的要求。 "创业投资被写进'十五五'规划建议，激动人 心，也给行业带来了重要变化。"陈玮表示，"创投的使命必须和国家的需要绑在一起，创投既要赚钱， 更要为国家所用，坚定支持人工智能、脑机接口、可控核聚变等领域的发展。" "顶层设计不 ...

Core Viewpoint - The continuous advancement of new technologies such as brain-computer interfaces, artificial intelligence, and the Internet of Things is expected to provide breakthroughs in previously challenging medical issues and unsolved healthcare problems [1] Group 1: Role of National Regional Medical Centers - National regional medical centers, equipped with strong research capabilities and high-level talent, can deeply engage in clinical practice while understanding patient needs, thus driving medical technology innovation [1] - To lead in medical innovation, healthcare institutions must strengthen their internal capabilities and establish integrated platforms for industry, academia, research, and application [1] Group 2: Strategies for Medical Innovation - Establishing research outpatient clinics can help doctors identify problems from clinical practice, enhancing the quality and relevance of research [1] - A reformed research evaluation system is necessary to encourage the identification of research topics from frontline clinical experiences, allowing clinical and research efforts to mutually benefit and ultimately serve public health [1] Group 3: Collaborative Innovation - Medical innovation is not a solitary endeavor but requires cross-disciplinary collaboration to achieve synergistic effects [1] - As a national team in medical innovation, national regional medical centers should actively expand their roles as cross-border hubs, collaborating with universities, research institutions, and enterprises to create a cooperative mechanism that shares demands, resources, and risks [1]

Core Viewpoint - The establishment of national regional medical centers in Fujian aims to reduce the burden on patients seeking medical care in major cities by providing high-quality medical services closer to home, significantly decreasing the number of patients needing to travel for treatment [8][9]. Group 1: National Regional Medical Center Development - Fujian has made significant progress in building national regional medical centers, with eight hospitals included in the initiative, ranking among the top in the country [8]. - The national regional medical centers have implemented measures such as expert support and standardized management, effectively addressing gaps in local healthcare for critical diseases [8][9]. - The collaboration between Fudan University Huashan Hospital and Fujian Medical University Affiliated First Hospital has resulted in the establishment of Huashan Affiliated First Hospital, recognized as one of the top ten pilot units for national regional medical centers [9][10]. Group 2: Patient Experiences and Treatment Outcomes - Patients like Chen Ping and Wang Xia have benefited from advanced treatments at Huashan Affiliated First Hospital, which previously required travel to major cities for care [10][14]. - The hospital has successfully performed complex surgeries and implemented innovative treatment plans, leading to significant improvements in patient health outcomes [12][16]. - The hospital's approach has resulted in a substantial increase in outpatient visits and inpatient admissions, with over 160,000 outpatient visits and 130,000 inpatient admissions recorded [17]. Group 3: Resource Integration and Innovation - The integration of resources between Huashan Hospital and Huashan Affiliated First Hospital has led to the establishment of specialized departments and enhanced clinical capabilities [21][22]. - The hospital has introduced innovative services such as "no card face recognition" for medical visits, improving patient experience and accessibility [22]. - The clinical pharmacology research center at Huashan Affiliated First Hospital has successfully conducted over 20 clinical trials, marking a significant advancement in the region's clinical research capabilities [24][26]. Group 4: Future Development and Strategic Goals - The hospital aims to continue expanding its clinical research and innovation efforts, focusing on high-end medical technologies and treatments [24][27]. - Plans are in place to enhance the hospital's capabilities in neurotechnology and other advanced medical fields, positioning it as a leader in regional healthcare [27][28]. - The strategic vision includes fostering collaboration between academic research and practical healthcare applications to drive regional medical advancements [28].